Literature DB >> 27592119

Diabetic ketosis during hyperglycemic crisis is associated with decreased all-cause mortality in patients with type 2 diabetes mellitus.

Ivan Kruljac1, Miroslav Ćaćić2, Petra Ćaćić3, Vedran Ostojić4, Mario Štefanović5, Aljoša Šikić6, Milan Vrkljan2.   

Abstract

Patients with type 2 diabetes mellitus have impaired ketogenesis due to high serum insulin and low growth hormone levels. Evidence exists that ketone bodies might improve kidney and cardiac function. In theory, improved ketogenesis in diabetics may have positive effects. We aimed to assess the impact of diabetic ketosis on all-cause mortality in patients with type 2 diabetes mellitus presenting with hyperglycemic crisis. We analyzed 486 patients with diabetic ketosis and 486 age and sex-matched patients with non-ketotic hyperglycemia presenting to the emergency department. Cox proportional hazard models were used to analyze the link between patient characteristics and mortality. During an observation time of 33.4 months, death of any cause occurred in 40.9 % of the non-ketotic hyperglycemia group and 30.2 % of the DK group (hazard ratio in the diabetic ketosis group, 0.63; 95 % confidence interval 0.48-0.82; P = 0.0005). Patients with diabetic ketosis had a lower incidence of symptomatic heart failure and had improved renal function. They used less furosemide and antihypertensive drugs, more metformin and lower insulin doses, all of which was independently associated with decreased mortality. Plasma glucose and glycated hemoglobin levels were similar in both groups. Patients with hyperglycemic crisis and diabetic ketosis have decreased all-cause mortality when compared to those with non-ketotic hyperglycemia. diabetic ketosis might be a compensatory mechanism rather than a complication in patients with hyperglycemic crises, but further prospective studies are warranted.

Entities:  

Keywords:  Heart failure; Ketogenesis; Ketosis; Kidney disease; Mortality; Type 2 diabetes mellitus

Mesh:

Year:  2016        PMID: 27592119     DOI: 10.1007/s12020-016-1082-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  20 in total

1.  Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes.

Authors:  Christian Wolfrum; Esra Asilmaz; Edlira Luca; Jeffrey M Friedman; Markus Stoffel
Journal:  Nature       Date:  2004-12-23       Impact factor: 49.962

2.  Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality.

Authors:  C Ll Morgan; J Mukherjee; S Jenkins-Jones; S E Holden; C J Currie
Journal:  Diabetes Obes Metab       Date:  2014-05-22       Impact factor: 6.577

Review 3.  Regulation of in vivo ketogenesis: role of free fatty acids and control by epinephrine, thyroid hormones, insulin and glucagon.

Authors:  M Beylot
Journal:  Diabetes Metab       Date:  1996-10       Impact factor: 6.041

4.  Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.

Authors:  C A Bannister; S E Holden; S Jenkins-Jones; C Ll Morgan; J P Halcox; G Schernthaner; J Mukherjee; C J Currie
Journal:  Diabetes Obes Metab       Date:  2014-07-31       Impact factor: 6.577

5.  Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.

Authors:  Ele Ferrannini; Simona Baldi; Silvia Frascerra; Brenno Astiarraga; Tim Heise; Roberto Bizzotto; Andrea Mari; Thomas R Pieber; Elza Muscelli
Journal:  Diabetes       Date:  2016-02-09       Impact factor: 9.461

6.  Stereoselective effects of 3-hydroxybutyrate on glucose utilization of rat cardiomyocytes.

Authors:  Yih-Chiao Tsai; Yu-Ching Chou; An-Bang Wu; Chien-Ming Hu; Chau-Yang Chen; Fu-An Chen; Jen-Ai Lee
Journal:  Life Sci       Date:  2005-10-12       Impact factor: 5.037

7.  Evidence for a role for insulin and growth hormone in overnight regulation of 3-hydroxybutyrate in normal and diabetic adolescents.

Authors:  J A Edge; D A Harris; P E Phillips; B R Pal; D R Matthews; D B Dunger
Journal:  Diabetes Care       Date:  1993-07       Impact factor: 19.112

8.  Glomerular filtration rate is increased in man by the infusion of both D,L-3-hydroxybutyric acid and sodium D,L-3-hydroxybutyrate.

Authors:  P Fioretto; R Trevisan; M Velussi; A Cernigoi; C De Riva; M Bressan; A Doria; N Pauletto; P Angeli; C De Donà
Journal:  J Clin Endocrinol Metab       Date:  1987-08       Impact factor: 5.958

9.  The Failing Heart Relies on Ketone Bodies as a Fuel.

Authors:  Gregory Aubert; Ola J Martin; Julie L Horton; Ling Lai; Rick B Vega; Teresa C Leone; Timothy Koves; Stephen J Gardell; Marcus Krüger; Charles L Hoppel; E Douglas Lewandowski; Peter A Crawford; Deborah M Muoio; Daniel P Kelly
Journal:  Circulation       Date:  2016-01-27       Impact factor: 29.690

10.  Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.

Authors:  Uchenna Anyanwagu; Jil Mamza; Rajnikant Mehta; Richard Donnelly; Iskandar Idris
Journal:  Heart       Date:  2016-05-23       Impact factor: 5.994

View more
  9 in total

Review 1.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.

Authors:  Guanghong Jia; Michael A Hill; James R Sowers
Journal:  Circ Res       Date:  2018-02-16       Impact factor: 17.367

2.  Green Tea Polyphenols Ameliorate the Early Renal Damage Induced by a High-Fat Diet via Ketogenesis/SIRT3 Pathway.

Authors:  Weijie Yi; Xiao Xie; Miying Du; Yongjun Bu; Nannan Wu; Hui Yang; Chong Tian; Fangyi Xu; Siyun Xiang; Piwei Zhang; Zhuo Chen; Xuezhi Zuo; Chenjiang Ying
Journal:  Oxid Med Cell Longev       Date:  2017-07-26       Impact factor: 6.543

3.  Metabolic Remodeling in Diabetic Cardiomyopathy.

Authors:  Cher-Rin Chong; Kieran Clarke; Eylem Levelt
Journal:  Cardiovasc Res       Date:  2017-02-08       Impact factor: 10.787

Review 4.  Immunometabolic cross-talk in the inflamed heart.

Authors:  Federica M Marelli-Berg; Dunja Aksentijevic
Journal:  Cell Stress       Date:  2019-06-07

Review 5.  Ketone body metabolism in diabetic and non-diabetic heart failure.

Authors:  Ningjing Qian; Yaping Wang
Journal:  Heart Fail Rev       Date:  2020-09       Impact factor: 4.214

6.  The Corrected Serum Sodium Concentration in Hyperglycemic Crises: Computation and Clinical Applications.

Authors:  Todd S Ing; Kavitha Ganta; Gautam Bhave; Susie Q Lew; Emmanuel I Agaba; Christos Argyropoulos; Antonios H Tzamaloukas
Journal:  Front Med (Lausanne)       Date:  2020-08-25

Review 7.  SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy.

Authors:  Na Li; Hong Zhou
Journal:  Drug Des Devel Ther       Date:  2020-11-06       Impact factor: 4.162

8.  Increased Glucose Availability Attenuates Myocardial Ketone Body Utilization.

Authors:  Manoja K Brahma; Chae-Myeong Ha; Mark E Pepin; Sobuj Mia; Zhihuan Sun; John C Chatham; Kirk M Habegger; Evan Dale Abel; Andrew J Paterson; Martin E Young; Adam R Wende
Journal:  J Am Heart Assoc       Date:  2020-07-30       Impact factor: 5.501

9.  Ketone Ester D-β-Hydroxybutyrate-(R)-1,3 Butanediol Prevents Decline in Cardiac Function in Type 2 Diabetic Mice.

Authors:  Phung N Thai; Charles V Miller; M Todd King; Saul Schaefer; Richard L Veech; Nipavan Chiamvimonvat; Donald M Bers; Elena N Dedkova
Journal:  J Am Heart Assoc       Date:  2021-09-29       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.